Division of Cardiology, Department of Internal Medicine, Tainan, Taiwan.
J Formos Med Assoc. 2010 Feb;109(2):113-9. doi: 10.1016/S0929-6646(10)60031-9.
BACKGROUND/PURPOSE: Thiazolidinediones have anti-atherothrombotic effects in diabetic patients. However, the effects of rosiglitazone on inflammatory and hemostatic markers, as well as global endothelial function in non-diabetic smokers are unknown.
Twenty-seven healthy male heavy smokers without metabolic syndrome were enrolled in this double-blind, controlled study. Fourteen subjects received 4 mg/day rosiglitazone for 8 weeks (group R) and 13 subjects received placebo (group C). Changes in the reflection index (Delta RI) of beta-agonist-induced endothelium-dependent vasodilatation by photoplethysmography and plasma biomarkers were measured before and after treatment.
Matrix metalloproteinase-9, fibrinogen, and high-sensitivity C-reactive protein were reduced significantly in group R after treatment as compared with the baseline [84.1 (45.6 139.0) vs. 123.9 (58.4 141.8) ng/mL, p = 0.03; 2914 (2400-3553) vs. 3220 (2542-3940) mg/L, p = 0.04; and 3.4 (2.2 5.1) vs. 5.5 (4.1 6.8) mg/L, p = 0.009, respectively]. Delta RI was improved markedly in group R as compared with the baseline [13.5 (4.2 65.1) vs. 2.5 (-10.6 to 9.3)%; p = 0.024]. These biomarkers and Delta RI did not differ significantly in the group C. There were no significant changes in fasting plasma glucose, insulin, homeostasis model assessment index, and lipid profile in both groups R and group C.
Rosiglitazone significantly reduces plasma levels of inflammatory and hemostatic biomarkers, and restores global endothelial dysfunction, independently from insulin sensitization, in healthy smokers.
背景/目的：噻唑烷二酮类药物在糖尿病患者中有抗动脉粥样硬化血栓形成的作用。然而，罗格列酮对非糖尿病吸烟者的炎症和止血标志物以及整体内皮功能的影响尚不清楚。
本双盲对照研究共纳入 27 名无代谢综合征的健康男性重度吸烟者。14 名受试者接受每天 4 毫克罗格列酮治疗 8 周（R 组），13 名受试者接受安慰剂（C 组）。治疗前后通过光体积描记法测量β激动剂诱导的内皮依赖性血管舒张的反射指数（Delta RI）和血浆生物标志物的变化。
与基线相比，R 组治疗后基质金属蛋白酶-9、纤维蛋白原和高敏 C 反应蛋白显著降低[84.1（45.6-139.0）与 123.9（58.4-141.8）ng/mL，p=0.03；2914（2400-3553）与 3220（2542-3940）mg/L，p=0.04；3.4（2.2-5.1）与 5.5（4.1-6.8）mg/L，p=0.009]。与基线相比，R 组 Delta RI 明显改善[13.5（4.2-65.1）与 2.5（-10.6-9.3）%，p=0.024]。C 组这些生物标志物和 Delta RI 没有显著差异。R 组和 C 组空腹血糖、胰岛素、稳态模型评估指数和血脂谱均无明显变化。
罗格列酮可显著降低健康吸烟者的炎症和止血标志物水平，并恢复整体内皮功能障碍，而与胰岛素敏感性无关。
